BMP-2-induced bone formation and neural inflammation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28367006)

Published in J Orthop on March 20, 2017

Authors

Vi Nguyen1, Carolyn A Meyers1, Noah Yan1, Shailesh Agarwal2, Benjamin Levi2, Aaron W James1

Author Affiliations

1: Department of Pathology, Johns Hopkins University, 21205, United States.
2: Department of Surgery, University of Michigan, 48109, United States.

Articles cited by this

Bone: formation by autoinduction. Science (1965) 13.34

Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA (2009) 4.07

Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med (2013) 4.02

Complications associated with single-level transforaminal lumbar interbody fusion. Spine J (2009) 2.99

Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) (2002) 2.74

Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech (2002) 2.54

A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery (2008) 2.39

Transforaminal lumbar interbody fusion: clinical and radiographic results and complications in 100 consecutive patients. J Spinal Disord Tech (2005) 2.27

Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) (2010) 2.24

Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) (2006) 2.19

A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976) (2003) 1.97

Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine (2005) 1.93

High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A (2011) 1.87

Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J (2004) 1.84

Perioperative complications in transforaminal lumbar interbody fusion versus anterior-posterior reconstruction for lumbar disc degeneration and instability. J Spinal Disord Tech (2006) 1.75

Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine (Phila Pa 1976) (2009) 1.59

Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J (2014) 1.52

RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976) (2008) 1.35

Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount. Surg Neurol Int (2013) 1.27

Occipitocervical fusion using recombinant human bone morphogenetic protein-2: adverse effects due to tissue swelling and seroma. Spine (Phila Pa 1976) (2008) 1.24

Cytokine-mediated inflammatory reaction following posterior cervical decompression and fusion associated with recombinant human bone morphogenetic protein-2: a case study. Spine (Phila Pa 1976) (2010) 1.20

Formation of painful seroma and edema after the use of recombinant human bone morphogenetic protein-2 in posterolateral lumbar spine fusions. Neurosurgery (2010) 1.08

BMP induced inflammation: a comparison of rhBMP-7 and rhBMP-2. J Orthop Res (2012) 1.07

Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures. Clin Orthop Relat Res (2012) 1.01

BMP2-induced inflammation can be suppressed by the osteoinductive growth factor NELL-1. Tissue Eng Part A (2013) 0.99

Activin and bone morphogenetic proteins induce calcitonin gene-related peptide in embryonic sensory neurons in vitro. Mol Cell Neurosci (1999) 0.97

Inflammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model. Spine (Phila Pa 1976) (2011) 0.95

Neurogenic substance P stimulates osteogenesis in vitro. Peptides (1997) 0.95

BMP-2/PLGA delayed-release microspheres composite graft, selection of bone particulate diameters, and prevention of aseptic inflammation for bone tissue engineering. Ann Biomed Eng (2010) 0.93

Bone morphogenetic proteins: basic concepts. Neurosurg Focus (2002) 0.91

Bone morphogenetic protein-binding peptide reduces the inflammatory response to recombinant human bone morphogenetic protein-2 and recombinant human bone morphogenetic protein-7 in a rodent model of soft-tissue inflammation. Spine J (2011) 0.88

A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Eng Part B Rev (2016) 0.87

Statins decrease expression of the proinflammatory neuropeptides calcitonin gene-related peptide and substance P in sensory neurons. J Pharmacol Exp Ther (2007) 0.86

Are BMPs involved in normal nerve and following transection?: a pilot study. Clin Orthop Relat Res (2009) 0.86

Delivery of bone morphogenetic protein-2 and substance P using graphene oxide for bone regeneration. Int J Nanomedicine (2014) 0.85

Calcitonin gene related peptide enhances bone colony development in vitro. Clin Orthop Relat Res (1997) 0.83

BMP-2 adverse reactions treated with human dose equivalent dexamethasone in a rodent model of soft-tissue inflammation. Spine (Phila Pa 1976) (2013) 0.81

Histological investigation of osteoinductive properties of rh-BMP2 in a rat calvarial bone defect model. J Craniomaxillofac Surg (2004) 0.81

RhBMP-2 use in lumbar fusion surgery is associated with transient immediate post-operative leg pain. Eur Spine J (2011) 0.81

Calcitonin gene-related peptide stimulates BMP-2 expression and the differentiation of human osteoblast-like cells in vitro. Acta Pharmacol Sin (2013) 0.80

Bone morphogenetic protein-2 counterregulates interleukin-18 mRNA and protein in MC3T3-E1 mouse osteoblastic cells. Connect Tissue Res (2006) 0.80

Transforaminal lumbar interbody fusion and posterior lumbar interbody fusion utilizing BMP-2 in treatment of degenerative spondylolisthesis: neither safe nor cost effective. Surg Neurol Int (2013) 0.80

A review of the current published spinal literature regarding bone morphogenetic protein-2: an insight into potential bias. Curr Rev Musculoskelet Med (2014) 0.79

Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions. Spine (Phila Pa 1976) (2014) 0.78

Exaggerated inflammatory environment decreases BMP-2/ACS-induced ectopic bone mass in a rat model: implications for clinical use of BMP-2. Osteoarthritis Cartilage (2014) 0.78

A dual delivery of substance P and bone morphogenetic protein-2 for mesenchymal stem cell recruitment and bone regeneration. Tissue Eng Part A (2015) 0.77

Acute epidural lipedema: a novel entity and potential complication of bone morphogenetic protein use in lumbar spine fusion. Spine J (2013) 0.77